LZTR1 and NRAS

Data Source:
BioGRID (affinity chromatography technology, affinity chromatography technology, imaging technique, proximity labelling technology, proximity labelling technology, proximity labelling technology, enzymatic study)

		LZTR1	NRAS
Description		leucine zipper like transcription regulator 1	NRAS proto-oncogene, GTPase
Image		No pdb structure
GO Annotations	Cellular Component	Golgi Apparatus Endomembrane System Cul3-RING Ubiquitin Ligase Complex Recycling Endosome Membrane	Golgi Membrane Golgi Apparatus Plasma Membrane Membrane Extracellular Exosome Tertiary Granule Membrane
	Molecular Function	Protein Binding Small GTPase Binding	GTPase Activity Protein Binding GTP Binding GDP Binding Protein-containing Complex Binding
	Biological Process	Protein Ubiquitination Negative Regulation Of Ras Protein Signal Transduction	MAPK Cascade Positive Regulation Of Endothelial Cell Proliferation Stimulatory C-type Lectin Receptor Signaling Pathway Ras Protein Signal Transduction Neutrophil Degranulation
Pathways			SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants
Drugs
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
GWAS			Adult body size ( 32376654) Autism ( 24189344)
Interacting Genes		55 interacting genes: AATF ANKRD53 ASB12 BMPR1B CEBPZ CHAF1A CNOT6L E2F8 EHMT1 FANK1 GABARAPL2 HCLS1 HDAC4 HRAS IKBKG KDM2B KRAS L3MBTL3 MCM3 MED16 MED7 MYBL2 NR1H3 NRAS PAPOLG PARP1 POLR1B POLR2B POLR2E RAI1 RERE RIT1 RUVBL1 SCMH1 SND1 SP100 SREBF2 SSX4 STAT1 SUGP2 TAF11 TBX2 TCF19 TFAP2B TRIM5 TUBGCP4 WWP1 ZBTB1 ZNF137P ZNF175 ZNF451 ZNF490 ZNF584 ZNF714 ZZZ3	48 interacting genes: ACVR1 AKT1 ALDOB AOPEP ARAF ARHGAP4 BCL2 CCDC180 CORO2A CYLC2 DNAJB1 EEF1A1 FANCC FBP2 FRAT2 HEMGN HRAS LEF1 LZTR1 MAPK3 MAPKAP1 MTOR PIK3CA PIK3CG PLCE1 PPP2CB RACGAP1 RAF1 RAP1GDS1 RASA1 RASGRP2 RASSF5 RGL2 RGL3 RIN1 RPS20 SFRP4 SHOC2 SMAD1 SMAD4 SMURF2 SRI STX17 TDRD7 TRMO UBE2L3 WDR76 XPA
Entrez ID		8216	4893
HPRD ID		08992	01273
Ensembl ID		ENSG00000099949	ENSG00000213281
Uniprot IDs		A0A384NL67 Q8N653	P01111 Q5U091
PDB IDs			2N9C 3CON 5UHV 6E6H 6MPP 6ULI 6ULK 6ULN 6ULR 6UON 6WGH 6ZIO 6ZIR 6ZIZ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?